牛皮癣的创新。

IF 2.2 3区 医学 Q2 DERMATOLOGY Dermatologic Clinics Pub Date : 2024-09-10 DOI:10.1016/j.det.2024.08.001
Amylee Martin MD , Marina Kristy Ibraheim MD , Rohit Gupta MD , Jashin J. Wu MD
{"title":"牛皮癣的创新。","authors":"Amylee Martin MD , Marina Kristy Ibraheim MD , Rohit Gupta MD , Jashin J. Wu MD","doi":"10.1016/j.det.2024.08.001","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":55178,"journal":{"name":"Dermatologic Clinics","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Innovations in Psoriasis\",\"authors\":\"Amylee Martin MD , Marina Kristy Ibraheim MD , Rohit Gupta MD , Jashin J. Wu MD\",\"doi\":\"10.1016/j.det.2024.08.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":55178,\"journal\":{\"name\":\"Dermatologic Clinics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Clinics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0733863524000731\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Clinics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0733863524000731","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

尽管治疗银屑病的有效生物制剂层出不穷,但由于某些患者群体的需求尚未得到满足,新疗法仍在研究之中。本综述讨论了最近获得美国食品药品管理局(FDA)批准用于治疗银屑病的疗法,包括外用药 tapinarof 和 roflumilast、选择性抑制酪氨酸激酶 2 的口服小分子药物 deucravacitinib 以及 spesolimab,后者是一种抑制白细胞介素-36 的单克隆抗体,是首个获得 FDA 批准用于治疗泛发性脓疱型银屑病的疗法。此外,还重点介绍了正在研发中的其他疗法,如奥司司特(orismilast),以及用于预测生物反应的工具 Mind.Px。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Innovations in Psoriasis
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatologic Clinics
Dermatologic Clinics 医学-皮肤病学
CiteScore
4.50
自引率
0.00%
发文量
84
审稿时长
6-12 weeks
期刊介绍: Dermatologic Clinics brings you the most practical and comprehensive information on the treatment and care of skin disorders, complete with photos, drawings, and diagrams to illustrate points and demonstrate techniques. Published quarterly—in January, April, July, and October—each issue is devoted to a single timely topic related to clinical dermatology, including hair disorders, pediatric dermatology, autoinflammatory disorders, contact dermatitis, and more. From evaluation to treatment, Dermatologic Clinics covers what is most relevant to you in your practice.
期刊最新文献
Contents Innovation in Dermatology Copyright Contributors Forthcoming Issues
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1